IL6 and neoplasm: However, our work shows that anti-IL-6 therapy alone has only modest efficacy and does not synergize with checkpoint inhibitors, suggesting that anti-IL-6 monotherapy may not fully reverse Mφ-mediated immunosuppression to activate anti-tumor immunity.